Plague meningitis occurs 9–14 days after onset (particularly younger patients)
Therapeutic Considerations
Antibiotic evidence base
Historical perspective
Streptomycin established 1940s as first effective treatment
Chloramphenicol added for CNS penetration
Fluoroquinolones accepted 1990s–2000s based on in vitro data and animal models
Current evidence
CDC 2021 MMWR guidelines: most comprehensive current reference
Systematic review (Nelson et al., Clin Infect Dis 2020): individual case analysis 1937–2019
NEJM 2025 IMASOY trial: ciprofloxacin non-inferior to aminoglycoside-ciprofloxacin for bubonic plague
Septicemic plague evidence extrapolated; combination preferred for severe disease
Antibiotic resistance
Naturally susceptible; acquired resistance rare but documented
Multidrug-resistant Y. pestis reported in Madagascar (1997): resistance to all first-line agents
Bioterrorism concern: engineered resistance possible
Supportive care considerations
Surviving Sepsis Campaign applicability
Hour-1 bundle: lactate, blood cultures, broad-spectrum antibiotics, IV fluids, vasopressors
Class I recommendation for septic shock resuscitation
DIC management principles
Treat underlying cause (antibiotics) as primary DIC intervention
Transfusion support for active bleeding
Heparin not routinely recommended in plague-associated DIC
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for Plague (Septicemic)
About your condition
You were treated for septicemic plague, a severe bloodstream infection caused by the bacterium Yersinia pestis
Plague is a serious infection requiring full completion of your antibiotic course
Early follow-up is essential to monitor for late complications
Medications
Complete the full course of antibiotics prescribed even if you feel better
Do not skip doses or stop antibiotics early
Take oral antibiotics at evenly spaced intervals as directed
Activity and diet
Rest and gradually increase activity as strength returns
Maintain good hydration: at least 2 litres of fluid daily unless restricted
No specific dietary restrictions unless advised
Wound and skin care
Monitor any skin lesions, blackened areas, or digit color changes closely
Return to emergency department immediately if skin lesions worsen or spread
Hearing and kidney monitoring
If you received aminoglycoside antibiotics, follow up for hearing test and kidney function within 2–4 weeks
Return to emergency department immediately for
Recurrent fever or chills
New or worsening cough or coughing up blood
Confusion, severe headache, or stiff neck
Worsening skin lesions, new black areas, or digit color changes
Sudden severe abdominal pain
Decreased urine output or dark urine
Any new bleeding or bruising
Public health
Household members and close contacts will be contacted by public health for evaluation and preventive antibiotics
Report dead rodents or unusual animal die-offs near your home to local public health authorities
Flea and rodent control measures should be implemented at the exposure site
References
Guidelines and key sources
CDC 2021 MMWR guidelines (primary reference)
Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response
MMWR Recommendations and Reports 2021
PMID 34264565
Primary authority for antibiotic selection, dosing, duration, and post-exposure prophylaxis
Systematic review of individual cases
Nelson CA, Fleck-Derderian S, Cooley KM, et al. Antimicrobial Treatment of Human Plague: A Systematic Review of the Literature on Individual Cases, 1937–2019
Clinical Infectious Diseases 2020
PMID 32435802
Grounding for case fatality rates and treatment outcomes
Aggregate data systematic review
Godfred-Cato S, Cooley KM, Fleck-Derderian S, et al. Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial Efficacy, 1939–2019
Clinical Infectious Diseases 2020
PMID 32435800
Clinical and epidemiologic references
NEJM 2025 IMASOY trial
Randremanana RV, Raberahona M, Bourner J, et al. Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague
New England Journal of Medicine 2025
Ciprofloxacin monotherapy non-inferior to combination for bubonic plague
Prentice and Rahalison landmark review
Prentice MB, Rahalison L. Plague. Lancet 2007
PMID 17416264
Comprehensive pathophysiology and epidemiology reference
Bioterrorism management
Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a Biological Weapon: Medical and Public Health Management
JAMA 2000
Working Group on Civilian Biodefense consensus statement
Rapid diagnostic tests
Jullien S, Dissanayake HA, Chaplin M. Rapid Diagnostic Tests for Plague. Cochrane Database of Systematic Reviews 2020
F1 antigen RDT sensitivity 89–94% in endemic field settings
New Mexico case series
Hull HF, Montes JM, Mann JM. Septicemic Plague in New Mexico. Journal of Infectious Diseases 1987
PMID 3794395
US-specific epidemiology and clinical features
Natural history review
Barbieri R, Signoli M, Chevé D, et al. Yersinia pestis: The Natural History of Plague. Clinical Microbiology Reviews 2020
PMID 33298527
Historical and evolutionary context
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.